Abstract
Purpose of Review
The purpose of this review was to summarize important and updated information on sitosterolemia. Sitosterolemia is an inherited lipid disorder consisting of high levels of plasma plant sterols. This sterol storage condition is caused by biallelic loss-of-function genetic variants in either ABCG5 or ABCG8, leading to increased intestinal absorption and decreased hepatic excretion of plant sterols. Clinically, patients with sitosterolemia usually exhibit xanthomatosis, high levels of plasma cholesterol, and premature atherosclerotic disease, but presentation can be highly heterogeneous. Therefore, recognition of this condition requires a high level of suspicion, with confirmation upon genetic diagnosis or through measurement of plasma phytosterols. Treatment of sitosterolemia with both a plant sterol-restricted diet and the intestinal cholesterol absorption inhibitor ezetimibe can reduce efficiently the levels of plasma plant sterols, consisting in the first-line therapy for this disease.
Recent Findings
Since hypercholesterolemia is often present in individuals with sitosterolemia, it is important to search for genetic variants in ABCG5 and ABCG8 in patients with clinical criteria for familial hypercholesterolemia (FH), but no variants in FH implicated genes. Indeed, recent studies have suggested that genetic variants in ABCG5/ABCG8 can mimic FH, and even when in heterozygosis, they may potentially exacerbate the phenotype of patients with severe dyslipidemia.
Summary
Sitosterolemia is a genetic lipid disorder characterized by increased circulating levels of plant sterols and clinically manifested by xanthomatosis, hematologic disorders, and early atherosclerosis. Awareness about this condition, a rare, but commonly underdiagnosed and yet treatable cause of premature atherosclerotic disease, is imperative.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest. 1974;53(4):1033–43. First description of sitosterolemia in two sisters.
Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb. 2018;25(9):783–9. This is a didactic review of several aspects of sitosterolemia.
Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, et al. Diagnosis and management of sitosterolemia 2021. J Atheroscler Thromb. 2021;28(8):791–801. This study provided a recent overview of sitosterolemia, diagnostic as well as therapeutic tips, and the latest diagnostic criteria in Japan.
Brinton EA, Hopkins PN, Hegele RA, Geller AS, Polisecki EY, Diffenderfer MR, et al. The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol. 2018;12(1):152–61. This study suggested that about 4% of subjects with LDL-C concentrations ≥ 190 mg/dL have plasma b-sitosterol concentrations above the 99th percentile and about 0.3% have concentrations consistent with sitosterolemia. Therefore, this condition should be suspected in individuals with severe hypercholesterolemia.
Othman RA, Myrie SB, Jones PJ. Non-cholesterol sterols and cholesterol metabolism in sitosterolemia. Atherosclerosis. 2013;231(2):291–9.
Escola-Gil JC, Quesada H, Julve J, Martin-Campos JM, Cedo L, Blanco-Vaca F. Sitosterolemia: diagnosis, investigation, and management. Curr Atheroscler Rep. 2014;16(7):424.
Tzavella E, Hatzimichael E, Kostara C, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: a multifaceted metabolic disorder with important clinical consequences. J Clin Lipidol. 2017;11(4):1095–100.
Salen G, Horak I, Rothkopf M, Cohen JL, Speck J, Tint GS, et al. Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res. 1985;26(9):1126–33.
Rubis B, Paszel A, Kaczmarek M, Rudzinska M, Jelen H, Rybczynska M. Beneficial or harmful influence of phytosterols on human cells? Br J Nutr. 2008;100(6):1183–91. https://doi.org/10.1017/S0007114508981423
Bao L, Li Y, Deng SX, Landry D, Tabas I. Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages. J Biol Chem. 2006;281(44):33635–49.
Plat J, Brzezinka H, Lutjohann D, Mensink RP, von Bergmann K. Oxidized plant sterols in human serum and lipid infusions as measured by combined gas-liquid chromatography-mass spectrometry. J Lipid Res. 2001;42(12):2030–8.
Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001;69(2):278–90.
Bastida JM, Benito R, Gonzalez-Porras JR, Rivera J. ABCG5 and ABCG8 gene variations associated with sitosterolemia and platelet dysfunction. Platelets. 2021;32(4):573–7.
Tada MT, Rocha VZ, Lima IR, Oliveira TGM, Chacra AP, Miname MH, et al. Screening of ABCG5 and ABCG8 genes for sitosterolemia in a familial hypercholesterolemia cascade screening program. CircGenom Precis Med. 2022:101161CIRCGEN121003390. In this study, the sequencing analysis of ABCG5/8 in a Brazilian hypercholesterolemic cohort lead to the identification of 14 patients with sitosterolemia with a high rate of early ASCVD. The study showed the importance of implementing genes associated with sitosterolemia in the FH genetic screening workup.
Yoo EG. Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab. 2016;21(1):7–14. This is a detailed review on several aspects of sitosterolemia.
Peterson AL, DeLine J, Korcarz CE, Dodge AM, Stein JH. Phenotypic Variability in atherosclerosis burden in an old-order amish family with homozygous sitosterolemia. JACC Case Rep. 2020;2(4):646–50.
Xia Y, Duan Y, Zheng W, Liang L, Zhang H, Luo X, et al. Clinical, genetic profile and therapy evaluation of 55 children and 5 adults with sitosterolemia. J Clin Lipidol. 2022;16(1):40–51. This study described the characteristics of a large Chinese cohort of 55 children and 5 adults with sitosterolemia.
Xu L, Wen W, Yang Y, Xie J, Li R, Wu Y, et al. Features of sitosterolemia in children. Am J Cardiol. 2020;125(9):1312–6.
Miettinen TA. Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest. 1980;10(1):27–35.
Kwiterovich PO Jr, Bachorik PS, Smith HH, McKusick VA, Connor WE, Teng B, et al. Hyperapobetalipoproteinaemia in two families with xanthomas and phytosterolaemia. Lancet. 1981;1(8218):466–9.
Kolovou G, Voudris V, Drogari E, Palatianos G, Cokkinos DV. Coronary bypass grafts in a young girl with sitosterolemia. Eur Heart J. 1996;17(6):965–6.
Katayama T, Satoh T, Yagi T, Hirose N, Kurita Y, Anzai T, et al. A 19-year-old man with myocardial infarction and sitosterolemia. Intern Med. 2003;42(7):591–4.
Yamada Y, Sugi K, Gatate Y, Senbonmatsu T, Inoue I, Fukushima K, et al. Premature acute myocardial infarction in a young patient with sitosterolemia. CJC Open. 2021;3(8):1085–8.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart J. 2017;38(32):2459–72.
Hansel B, Carrie A, Brun-Druc N, Leclert G, Chantepie S, Coiffard AS, et al. Premature atherosclerosis is not systematic in phytosterolemic patients: severe hypercholesterolemia as a confounding factor in five subjects. Atherosclerosis. 2014;234(1):162–8.
Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24. The results of this study suggested that mutations in ABCG5/ABCG8 can mimic and exacerbate the FH phenotype, supporting their investigation in individuals with severe hypercholesterolemia.
Gregg RE, Connor WE, Lin DS, Brewer HB Jr. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest. 1986;77(6):1864–72.
Parsons HG, Jamal R, Baylis B, Dias VC, Roncari D. A marked and sustained reduction in LDL sterols by diet and cholestyramine in beta-sitosterolemia. Clin Invest Med. 1995;18(5):389–400.
Belamarich PF, Deckelbaum RJ, Starc TJ, Dobrin BE, Tint GS, Salen G. Response to diet and cholestyramine in a patient with sitosterolemia. Pediatrics. 1990;86(6):977–81.
Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia–effect of ezetimibe on plant sterol metabolism. J Atheroscler Thromb. 2010;17(9):891–900.
Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.
Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109(8):966–71. This study showed that Ezetimibe produced significant and progressive reductions in plasma plant sterol concentrations in patients with sitosterolemia, consistent with the hypothesis that ezetimibe inhibits the intestinal absorption of plant sterols as well as cholesterol, leading to reductions in plasma concentrations.
Lutjohann D, von Bergmann K, Sirah W, Macdonell G, Johnson-Levonas AO, Shah A, et al. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract. 2008;62(10):1499–510.
Musliner T, Cselovszky D, Sirah W, McCrary Sisk C, Sapre A, Salen G, et al. Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia. Int J Clin Pract. 2008;62(7):995–1000.
Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, et al. Update of the Brazilian guideline for familial hypercholesterolemia - 2021. Arq Bras Cardiol. 2021;117(4):782–844.
Authors/Task Force M, Guidelines ESCCfP, Societies ESCNC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.
Niu DM, Chong KW, Hsu JH, Wu TJ, Yu HC, Huang CH, et al. Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children. J Inherit Metab Dis. 2010;33(4):437–43.
Nguyen LB, Cobb M, Shefer S, Salen G, Ness GC, Tint GS. Regulation of cholesterol biosynthesis in sitosterolemia: effects of lovastatin, cholestyramine, and dietary sterol restriction. J Lipid Res. 1991;32(12):1941–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
VZR has received honoraria from Aché, Amgen, Amryt, AstraZeneca, Biolab, Daiichi-Sankyo, GSK, Novartis, Novo Nordisk, and Sanofi.
MHM has received honoraria from Amgen.
MTT, APMC, and MHM declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rocha, V.Z., Tada, M.T., Chacra, A.P.M. et al. Update on Sitosterolemia and Atherosclerosis. Curr Atheroscler Rep 25, 181–187 (2023). https://doi.org/10.1007/s11883-023-01092-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11883-023-01092-4